Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies

Journal of Experimental Medicine

Volumn 210, Issue 4, 2013, Pages 655-663

  McGuire, Andrew T ^a   Hoot, Sam ^a   Dreyer, Anita M ^a   Lippy, Adriana ^a   Stuart, Andrew ^a   Cohen, Kristen W ^a,b   Jardine, Joseph ^c   Menis, Sergey ^c   Scheid, Johannes F ^d   West, Anthony P ^e   Schief, William R ^c   Stamatatos, Leonidas ^a,b  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e California Institute of Technology HHMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD4 ANTIBODY; VIRUS ENVELOPE PROTEIN; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; CALCIUM TRANSPORT; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; GENETICS; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PROTEIN SECONDARY STRUCTURE; TUMOR CELL LINE;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CELL LINE, TUMOR; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GLYCOSYLATION; HIV ANTIBODIES; HIV-1; HUMANS; PROTEIN ENGINEERING; PROTEIN STRUCTURE, SECONDARY;

MLCS; MLOWN;

EID: 84878626061     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20122824     Document Type: Article

References (29)

1. Binley, J.M., E.A. Lybarger, E.T. Crooks, M.S. Seaman, E. Gray, K.L. Davis, J.M. Decker, D. Wycuff, L. Harris, N. Hawkins, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668. http://dx.doi.org/10.1128/JVI.01762-08
2. Diskin, R., J.F. Scheid, P.M. Marcovecchio, A.P. West Jr., F. Klein, H. Gao, P.N. Gnanapragasam, A. Abadir, M.S. Seaman, M.C. Nussenzweig, and P.J. Bjorkman. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 334:1289-1293. http://dx.doi.org/10.1126/science.1213782
3. Gray, E.S., M.C. Madiga, T. Hermanus, P.L. Moore, C.K. Wibmer, N.L. Tumba, L. Werner, K. Mlisana, S. Sibeko, C. Williamson, et al; CAPRISA002 Study Team. 2011a. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840. http://dx.doi.org/10.1128/JVI.00198-11
4. Gray, G.E., M. Allen, Z. Moodie, G. Churchyard, L.G. Bekker, M. Nchabeleng, K. Mlisana, B. Metch, G. de Bruyn, M.H. Latka, et al; HVTN 503/Phambili study team. 2011b. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 11:507-515. http://dx.doi.org/10.1016/S1473-3099(11)70098-6
5. Hoot, S., A.T. McGuire, K.W. Cohen, R.K. Strong, L. Hangartner, F. Klein, R. Diskin, J.F. Scheid, D.N. Sather, D.R. Burton, and L. Stamatatos. 2013. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 9:e1003106. http://dx.doi.org/10.1371/journal.ppat.1003106
6. Horikawa, K., S.W. Martin, S.L. Pogue, K. Silver, K. Peng, K. Takatsu, and C.C. Goodnow. 2007. Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J. Exp. Med. 204:759-769. http://dx.doi.org/10.1084/jem.20061923
7. Huang, P.S., Y.E. Ban, F. Richter, I. Andre, R. Vernon, W.R. Schief, and D. Baker. 2011. RosettaRemodel: a generalized framework for flexible backbone protein design. PLoS ONE. 6:e24109. http://dx.doi.org/10.1371/journal.pone.0024109
8. Kwong, P.D., and J.R. Mascola. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012
9. Li, Y., S.A. Migueles, B. Welcher, K. Svehla, A. Phogat, M.K. Louder, X. Wu, G.M. Shaw, M. Connors, R.T. Wyatt, and J.R. Mascola. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034. http://dx.doi.org/10.1038/nm1624
10. Li, Y., S. O'Dell, L.M. Walker, X. Wu, J. Guenaga, Y. Feng, S.D. Schmidt, K. McKee, M.K. Louder, J.E. Ledgerwood, et al. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85:8954-8967. http://dx.doi.org/10.1128/JVI.00754-11
11. Ly, A., and L. Stamatatos. 2000. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 74:6769-6776. http://dx.doi.org/10.1128/JVI.74.15.6769-6776.2000
12. Lynch, R.M., L. Tran, M.K. Louder, S.D. Schmidt, M. Cohen, R. Dersimonian, Z. Euler, E.S. Gray, S. Abdool Karim, J. Kirchherr, et al; CHAVI 001 Clinical Team Members. 2012. The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86:7588-7595. http://dx.doi.org/10.1128/JVI.00734-12
13. Mascola, J.R., and D.C. Montefiori. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444. http://dx.doi.org/10.1146/annurev-immunol-030409-101256
14. Mikell, I., D.N. Sather, S.A. Kalams, M. Altfeld, G. Alter, and L. Stamatatos. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251. http://dx.doi.org/10.1371/journal.ppat.1001251
15. Ota, T., C. Doyle-Cooper, A.B. Cooper, M. Huber, E. Falkowska, K.J. Doores, L. Hangartner, K. Le, D. Sok, J. Jardine, et al. 2012. Anti-HIV B Cell lines as candidate vaccine biosensors. J. Immunol. 189:4816-4824. http://dx.doi.org/10.4049/jimmunol.1202165
16. Sather, D.N., J. Armann, L.K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and L. Stamatatos. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769. http://dx.doi.org/10.1128/JVI.02036-08
17. Saunders, C.J., R.A. McCaffrey, I. Zharkikh, Z. Kraft, S.E. Malenbaum, B. Burke, C. Cheng-Mayer, and L. Stamatatos. 2005. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J. Virol. 79:9069-9080. http://dx.doi.org/10.1128/JVI.79.14.9069-9080.2005
18. Scheid, J.F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 333:1633-1637. http://dx.doi.org/10.1126/science.1207227
19. Schief, W.R., Y.E. Ban, and L. Stamatatos. 2009. Challenges for structurebased HIV vaccine design. Curr Opin HIV AIDS. 4:431-440. http://dx.doi.org/10.1097/COH.0b013e32832e6184
20. Sellhorn, G., Z. Caldwell, C. Mineart, and L. Stamatatos. 2009. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine. 28:430-436. http://dx.doi.org/10.1016/j.vaccine.2009.10.028
21. Stamatatos, L. 2012. HIV vaccine design: the neutralizing antibody conundrum. Curr. Opin. Immunol. 24:316-323. http://dx.doi.org/10.1016/j.coi.2012.04.006
22. Waisman, A., M. Kraus, J. Seagal, S. Ghosh, D. Melamed, J. Song, Y. Sasaki, S. Classen, C. Lutz, F. Brombacher, et al. 2007. IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta. J. Exp. Med. 204:747-758. http://dx.doi.org/10.1084/jem.20062024
23. Wakabayashi, C., T. Adachi, J. Wienands, and T. Tsubata. 2002. A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science. 298:2392-2395. http://dx.doi.org/10.1126/science.1076963
24. West, A.P. Jr., R. Diskin, M.C. Nussenzweig, and P.J. Bjorkman. 2012. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA. 109:E2083-E2090. http://dx.doi.org/10.1073/pnas.1208984109
25. Wu, X., Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329:856-861. http://dx.doi.org/10.1126/science.1187659
26. Wu, X., T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N.S. Longo, M. Louder, K. McKee, et al; NISC Comparative Sequencing Program. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 333:1593-1602. http://dx.doi.org/10.1126/science.1207532
27. Wyatt, R., N. Sullivan, M. Thali, H. Repke, D. Ho, J. Robinson, M. Posner, and J. Sodroski. 1993. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557-4565.
28. Xiao, X., W. Chen, Y. Feng, Z. Zhu, P. Prabakaran, Y. Wang, M.Y. Zhang, N.S. Longo, and D.S. Dimitrov. 2009. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390: 404-409. http://dx.doi.org/10.1016/j.bbrc.2009.09.029
29. Zhou, T., I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 329:811-817. http://dx.doi.org/10.1126/science.1192819